1. No category

Innovation across disciplines
Biopeople:
Danish Innovation Cluster for
Life & Health Sciences
GÅ-Hjemmøde Horizon2020
23. januar 2014
Niels Westergaard, PhD, Dr pharm
Science and Innovation Network Manager
www.biopeople.dk
Biopeople
Innovation across disciplines
• We focus on setting up:
• cross disciplinary projects
• public private partnerships
• internationalisation.
• To reach these strategic goals, we use the
following services:
• matchmaking events
• knowledge transfer,
• innovation projects
• strategy development.
Cartoons: Jens Hage; www.hage.dk
3
Innovation across disciplines
Biopeople receives the European Cluster Excellence Initiative (ECEI) Gold Label
of Cluster Management Excellence in June 2013.
Based on expert assessment of 31 quality indicators
Endorsed by the European Commission
Biopeople is the first European Life Science Network to obtain that recognition
4
Horizon 2020
Innovation across disciplines
New framework programme for Research and
Innovation (2014-2020)
Biopeople to take an active role to stimulate the formation
of strong consortiums within life sciences and be an active
player in reference groups and advisory boards
Reference group:
• Health, Demographic Change and
Wellbeing
• Food Security and Biobased Economy
Matchmaking
Cartoons: Jens Hage; www.hage.dk
Horizon 2020
http://www.biopeople.dk/index.php?id=732
Innovation across disciplines
Innovation across disciplines
European Patients Academy on Therapeutic
Innovation (EUPATI)
http://www.patientsacademy.eu – info@patientsacademy.eu
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed
of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
Innovation across disciplines
IN2LifeSciences:
Access to Market, Technology and Financing fore SMEs
Shared among 8 bioregions, of which Denmark is one
~ 250 incentives:
€500, €4000 or €7000
Regional Access Brokers
Easy access to facilities
and experts
(this is not a logo)
Biopeople den 23. januar 2014
Anne-Mette Mikkelsen
EuroCenter
ammi@fi.dk
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
EuroCenter –
National Contact Point (NCP)
Vejledning til danske FP-7 og Horizon 2020 deltagere
Vejledning og rådgivning – fra projektidé til projektafslutning (via telefon, email, individuelle møder)
 Vejledning ift. juridiske og økonomiske regler
Tæt kontakt til Europa Kommissionen
Ansøgningsvejledning
Kurser om ansøgningsskrivning, rapportering,
koordinatorrollen mm.
www.rammeprogram.dk
Kontakt:
Telefon: 35446240
E-mail: Eurocenter@fi.dk
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Hvorfor 70 mia. € til forskning og innovation ?
• Styrke Europas position indenfor videnskab på den globale
scene
• Fremme Europas industrielle lederskab
• Adressere store samfundsmæssige udfordringer
skabe vækst og beskæftigelse i Europa
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Budget: 77 milliarder euros
INDUSTRIAL
LEADERSHIP
EXCELLENT
SCIENCE
European Research
Council
17%
Leadership in enabling
and industrial
technologies
17,6%
Future and Emerging
Technologies
Access to risk finance
3,69%
3,5%
Marie Sklodowska-Curie
actions
8%
Innovation in SMEs
SOCIETAL
CHALLENGES
Health, demographic
change and well-being;
Food security, sustainable
agriculture and forestry, marine
and maritime and inland water
research and the bioeconomy
5%
Secure, clean and efficient
energy;
7,7%
0,8%
Research Infrastructures
9,7%7
%
Smart, green and
integrated transport;
8,23%
3,23%
Widening Participation: 1,06%
Science with and for society: 0,6%
EIT: 3,52%
JRC: 2,47%
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Climate action, resource
efficiency and raw
materials;
4%
Inclusive, innovative and
reflective societies.
1,7%
Secure Societies
2,2%
Én type tilskudsrate per projekt
Projekttyper
Tilskudsrate
Research and
Innovation
Actions
100 % + 25 %
Innovation
Actions
70 % + 25 %
(100 % til non-profit)
Coordination &
Support Actions
100 % + 25 %
Dvs. at alle støtteberettigede udgifter i f.eks. et forskningsprojekt
støttes med 100 % + 25 % overhead uanset aktivitets- og partnertype,
70 % + 25 % i et innovationsprojekt (demonstration/close to market a.)…
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Muligheder for SMVer (I)
Forsknings- og innovationsprojekter, som udbydes i
arbejdsprogrammer (WP) under
Leadership in enabling and industrial technologies (søjle 2)
og Societal Challenges (søjle 3).




Time to grant: 8 måneder (5+3)
Konsortiekrav: Min. 3 partnere fra 3 forskellige EU-lande ell. ass. lande
Varighed: Typisk 3-5 år
Budgetstørrelse: Typisk 3-9mio euros
Spg vedr. wp for
bioteknologi og bioøkonomi
Kontakt NCP Ulrik K. Olsen
Telefon: 72318281
E-mail: uko@fi.dk
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Spg vedr. wp for sundhed
Kontakt NCP Kim Kryger
Telefon: 72318288
E-mail: klk@fi.dk
Muligheder for SMVer (II)
Fast track to innovation (projekttype fra 2015), som udbydes
i arbejdsprogrammer (WP) under søjle 2 og 3
 Bottom up – indenfor rammerne af det givne arbejdsprogram



Forventet tilskud ca. 3 millioner euros
Time-to grant max 6 måneder
Løbende ansøgningsfrist
Små konsortier (3-5 partnere)
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Muligheder for SMVer (III)
Marie Sklodowska Curie Actions (program under søjle 1)
“gratis” forsker eller ph.d (udstationering til virksomheden)
ITN- call’et (støtte til uddannelse af ph.d.-er)
- smv’en bliver del af en “ph.d-skole” med vidensinstitutioner
- smv’en bliver tilknyttet netværket og tager imod en ph.d.-studerende
i en periode
RISE-callet (støtte til staff exchange)
- smv’en deltager i et forskningsprojekt med vidensinstitutioner og får
tilskud fra EU til udveksling af personale
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Spg vedr. wp for MSC
Kontakt NCP Bodil Palmberg
Telefon: 72318263
E-mail: bep@fi.dk
Muligheder for SMVer ud (IV)
Eurostars (NB - særligt program med national medfinansiering).
 Primær målgruppe: innovations- og forskningsaktive SMV’er (anvender mindst
10 % af deres omsætning eller af deres fuldtidsansatte på FoU aktiviteter).
 Medfinansiering af forsknings- udviklings- og demonstrationsaktiviteter.
 Tværnationale konsortier (min. 2 deltagere fra 2 lande).
 Varighed: maximalt 3 år og 2 år til markedsføring efter projektafslutningen.
Biotek-projekter skal mindst være klar til klinisk fase ét to år efter
projektafslutningen.
 Uafhængigt internationalt bedømmelsespanel. Svar på ansøgning inden for 4-5
måneder.
 SMV’er kan få op til 50 % af projektomkostningerne dækket. Det maksimale
tilskudsbeløb pr. projekt er 300.000 € til de danske deltagere. De danske tilskud
dækker primært lønudgifter.
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Spg. vedr. EuroStars
Kontakt: Lisbet Elming
Telefon: 72318252
E-mail: lel@fi.dk
Muligheder for SMVer (V)
Budget: ca. 3 mia
euros
SMV-instrument (projekttype, som udbydes i arbejdsprogrammer
(WP) under søjle 2 og 3)
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Fase 1
Konsortiekrav:
Min. 1 smv
Concept &
Feasibility
Assessment
Ansøgningsfrist:
Løbende ansøgning
Time to grant:
3 måneder
Projektvarighed:
6 måneder
Budgetstørrelse:
50.000 euros (70 %)
Ansøgning:
10 sider
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Fase 2
Demonstration
Market Replication
Research
Development
Miniaturisation
Testing
Piloting
Prototyping
Scaling up
Kan søges direkte
uden forudgående
deltagelse i fase 1
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Konsortiekrav:
Min. 1 smv
Ansøgningsfrist:
Løbende ansøgning
Time to grant:
6 måneder
Projektvarighed:
12-24 måneder
Budgetstørrelse:
Typisk 0.5-2.5 mio euros (70 %)
Ansøgning:
30 sider
Concept &
Feasibility
Assessment
Demonstration
Market Replication
Research
Development
Miniaturisation
Testing
Piloting
Prototyping
Scaling up
Support –
No direct funding
IDEA business coaching throughout the project
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
MARKET
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Nyttige links
Deltagerportalen (participant portal) hvor al information om H2020 findes:
http://ec.europa.eu/research/participants/portal/desktop/en/home.html
Genvej til arbejdsprogrammer, regler for deltagelse, ansøgningsskabeloner mm:
http://ec.europa.eu/research/participants/portal/desktop/en/funding/reference
_docs.html
Ansøgningsskabelon fase 1 SMV-instrumentet:
http://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/h2020call-pt-sme-1_en.pdf
Ansøgningsskabelon fase 2 SMV-instrumentet:
http://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/h2020call-pt-sme-2_en.pdf
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
EUopSTART
EUopSTART yder tilskud til danske virksomheders og
videninstitutioners forberedende arbejde med at deltage i
udvalgte europæiske og internationale forskningsprogrammer.
EUopSTART giver støtte til forberedelse af ansøgninger til
Horizon 2020
Puljen åbner igen 1. juli 2014
Kontakt
Helle Poulsen
Telefon: 72318251
E-mail: hepo@fi.dk
www.fivu.dk/euopstart
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
Ea Elisabeth Bauchy
Telefon: 72318247
E-mail: eeb@fi.dk
Ministeriet for Forskning, Innovation
og Videregående Uddannelser
Styrelsen for Forskning og Innovation
www.eusupport.dk
January, 2014
Copenhagen Bio Science Park
Experience gained from working in EU framework
programs
Peter Mouritzen, MSc, PhD
VP R&D
Agenda
2
● Introduction to Exiqon today
● How did we get there
● A historic perspective on the role of EU FP
projects
● Exiqon Roles in EU FP projects
● Workload of roles
● Internal guidelines
Exiqon at a glance
Highlights
Locations
• Based on proprietary LNA™ detection technology
• Established one-stop shop for miRNA products
• Promising diagnostic pipeline based on miRNA
• 214 patents and patent applications (114 issued)
cover products, pipeline and miRNA biomarkers
Exiqon facilities
Distributors
Business divisions
Life Sciences
• Exiqon Life Sciences combines leading-edge
scientific expertise in gene expression with our
proprietary LNA™ technology. Our products,
services and scientific staff enable life science
researchers to make groundbreaking discoveries
Diagnostics
Exiqon Diagnostics is the leader in providing
technologies for miRNA biomarker detection. Exiqon
Diagnostics is dedicated in collaboration with partners
to develop novel molecular diagnostic tests for early
detection of diseases and knowledge based treatment
selection.
Exiqon at a glance
- We took innovation conducted at universities into commercial success
4
• Exiqon develops, manufactures and sell products for genetic testing addressing a 12 billion USD market
• 98% of products sold are exported. 60% are exported out of EU
mDKK
• >75 highly educated employees (40% has a Ph.D.) from >10 nationalities
• Knowhow: Molecular & cell biology, (bio)chemistry, bioinformatics, robotics and IT
25
• Raised 600 mDKK in risk capital
20
15
Our proprietary
technology
Exiqon in-licensed
was invented
the technology
at U of CPH and
Osaka University
First product
launched
10
5
0
1997
2000
2004
Q1
2006
Q4
2012
LNA™ technology overview
LNA™ technology increases binding affinity
•
LNA is a bicyclic high affinity RNA mimic with the
sugar ring locked in the 3’-endo conformation
•
•
•
•
Stable A-helix with good base-stacking
•
•
Obeys Watson-Crick base-pairing rules
Increased Tm (Tm increases by 2 - 8ºC per base)
Improved mismatch discrimination
High sensitivity and specificity in hybridization
assays
Easy to implement in standard oligo synthesis
K. Bondensgaard et al., Chem. Eur. J. 2000, 6, 2687
M. Petersen et al., J. Am. Chem. Soc. 2002, 124, 5974
MicroRNA research: Broad product portfolio
Exiqon Diagnostic Pipeline
Diagnostic Product Development
Colorectal Cancer (Recurrence stage II test )
Colorectal Cancer (Early detection diagnostic test)
Prostate Cancer (Diagnostic and prognostic test)
NGS precision medicine
RUO kit in 2014
Synergies within business areas
Life Sciences
•
•
•
Diagnostics
Molecular tools
microRNA profiling platforms
Protocols
•
•
•
microRNA as biomarkers
Biofluids – serum, plasma, urine, CSF
Protocols
•
•
•
•
Exiqon Core lab
Centralized expertise
In house experts with our own products
Protocol validation
Experience
&
Innovation
Exiqon Services
Important events in building one-stop shop for miRNA
products
Wienholds et al
Science
4000
3500
Papers
3000
2500
2000
Development
Development
Start RIBOREG
&
of 1st miRNA
of of
first miRNA
Development
LNA™ PCR
miRNA LNA™ LNA™
ISH probesmicroarray
1500
1000
500
0
lin-4,
critical for C.elegans
developmental timing
Development
of 2nd miRNA
LNA™ PCR
miRNAs found
in mouse &
human
miRNAs
implicated
in cancer
miRNAs
implicated in
viral infection
miRNA papers
per year
according to
PubMed
Excellent timing for product development and
perfect application for LNA™
Exiqon in 2004
• ~20 employees
• Large R&D organization
• LNA™ oligo business
10
RIBOREG FP6 project
• 36 month project duration
• 250 T EUR Grant
• 9 partners
• Work package leader role
RIBOREG
Identification of
putative precursors
of si/mi RNAs
WP1
Identifica tion of
new large noncoding RNAs
Transfer to WP3
or new non-coding
RNAs for exp ression
study
WP5
Co-ordination and Management
WP2
Identifica tion of
new si/miRNA s,
their precursors
and targets
Transfer to WP3
or new non-coding
mi/si RNAs for
expression studies
WP3
Determin ation of the
expressio n patterns of
non-codin g RNA genes
WP4
Dissectio n of molecula r
mechanisms involving
non-codin g RNAs
Selection of most interesting
non-coding RNAs for WP4
European Commission and the European
Scientific and Industrial Communities
Experiences from >7 EU FP projects
11
5-10 invites per year to join EU projects
● Roles
● Work Package leader
● Contributing partner
● Initiative taker
● Tasks
●
●
●
●
Proposal writing
coordination of reporting - Some workload
own scientific reporting - Moderate workload
Financial reporting
Innovation at Exiqon
- Publicly funded projects is one pillar in our innovation strategy
Innovation at Exiqon:
• Internal “Innovation Challenge”
• In collaboration with customers
• Based on public funding with academic partners
We use externally funded programs to:
• Access specific knowhow
• Access to “key opinion leaders”
• Get the products validated and tested
• Get access to relevant biological material
12
EU funded programs have been instrumental to Exiqon
13
- Public funded projects work
Program
Number of
partners
Total budget/Exiqon budget
Commercial outcome (Exiqon)
Riboreg/FP6
9
Initiated 80% of our product portfolio
Sirocco/FP6
20
16,0 / 0,6 mEUR
Very limited
Oncomirs/FP7
6
4,3 / 0,6 mEUR
Development of the fastest growing
product line
Prosper/FP7
7
4,0 / 0,6 mEUR
Launch March 2013
Colon cancer/HTF
4
42 / 28 mDKK
Best selling product
Riboreg was the most successful EU program so far – it was used by EU to showcase FP6:
From concluding report:
” They note that the collaboration in the RIBOREG project has
allowed speeding up the development of the LNA probe technology
and Exiqon has been able to commercialize a number of
products based on this technology”
Learning from public funded programs
14
Learning:
• The fewer partners the better
• Project leadership is essential: Best when project leader is in company
• Commercial outcome: The innovation is often applied in products for other markets than originally
intended
• Innovation from publicly funded programs only results in commercial success when it simultaneously is
supported by risk capital e.g. Riboreg was launched in the financial “heydays”
Without money, innovation is worth nothing
- Access to risk capital is essential.
15
• Even within established organizations it is expensive to take new products to the global market
• The actual product development, manufacturing processes, marketing and selling process cost more in
working capital than received in public funding
Demand for risk capital
In SME’s (cash flow negative) that is funded by risk capital
Innovation creates value once the need for risk capital is addressed
16
- We can do it much better
E.g. on financial audit manuals
On public funded innovation programs:
FP7: 107pages + 96 pages
HTF: 15 pages + 15 pages
In FP7 programs, Exiqon has spend
• Simplify management of public funded EU programs
5% of the budget on
internal financial control
• Increase focus on project management
• Fund fewer programs with fewer participants but make programs more ambitious = better funded
On commercialization of innovation:
• It is very costly to take public funded innovation into commercial products
• It takes time: In Life Sciences 5-10 years is common
• We can only harvest the commercial potential if DK (EU) improve the access to risk capital
Exiqon guidelines in considering participation
17
● Hire a professional coordinator
●
●
A lot of ressouces writing
Interacting with the commision
● Don’t get involved if you have to do a lot of stuff you did not intend to
● Only participate if this will take you the way you planned anyway
● Ultimately, initiate the project yourself
● Challenges beeing a partner supermarket for consumables
Summary
● EU projects may be a good way to
●
Access specific knowhow
●
Access KOLs
●
Get the products validated and tested
●
Get access to relevant biological material
● Consider alignment of project with overall company strategy
● Devote a partner role to project coordination
Thank you
Contact information:
VP R&D Peter Mouritzen
pm@exiqon.com
Horizon2020 Netværksmøde
Hos BioPeople
23. januar 2014.
Christina Yoon Petersen
EUhelp.dk – euhelp@euhelp.dk - Tlf.: 29 25 45 66
Erfaring
• Revideret for EU via Moore Stephens
• Revideret FP6 via PwC
• Afrapporteret Form C FP6 og FP7 via GEUS, KU og
virksomheder.
Horizon2020
Få hjælp fra en række aktører.
• Private
• Innovationsnetværk/BioPeople
• Offentlige Styrelser
• Universiteter/forskningsinstitutioner
• GTS
• Virksomheder
• Udlandet
Offentlige
• EuroCenter
• Agropark (partnerskab)
• EU DK support
• Innovationsnetværk/BioPeople
• Universiteter: KU, DTU, Århus Universitet
• GTS (halv offentligt)
• Andre forskningsinstitutioner
Private
• Innovayt
• 1stmile
• Wiborg
• Anders Bjerrum
• Udenlandske (hyperion, G & H Associates Limited)
• EUhelp
• Revision: Deloitte eller PwC
Regler og dokumentation
Ansøgning:
• Højteknologifonden (Innovationsfonden) - erfaring
• Private/offentlige aktører
Dokumentation/revisor:
• EUhelp
• Deloitte/PwC
• Bogholder med erfaring fra fx en forskningsinstitution.
• Eurocenter (inkl. Kurser)
Netværk
• BioPeople og Netmatch (Innovationsnetværk)
• Kurser og arrangementer hos Eurocenter
• Dansk Industri og Dansk Erhverv
• Arrangementer hos universiteterne
(Erhvervssamarbejder, forskerparker etc.)
• Udenlandske universiteter/virksomheder.
• EUhelps netværksarrangementer
Netværksarrangement
23. maj 2014.
• ”Adgang til finansiering”
• I samarbejde med Deloitte.
• Oplægsholdere.
• Idéen med at hjælpe hinanden.
• Fredagsbar.
• Tidligere arrangementer